TY - JOUR
T1 - Evaluation of bioprinter technologies
AU - Ozbolat, Ibrahim T.
AU - Moncal, Kazim K.
AU - Gudapati, Hemanth
N1 - Funding Information:
This work was supported by the US National Science Foundation CMMI Awards1349716 and 1462232, Diabetes in Action Research and Education Foundation grant # 426 and the Osteology Foundation Grant # 15-042. The authors also acknowledge the support from the Engineering Science and Mechanics Department at Penn State University. The authors would like to thank Alyssa Sipos, Donna Sosnoski and Madhuri Dey from the Pennsylvania State University for their assistance with typesetting and Fig. 4. The authors confirm that there are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Since the first printing of biologics with cytoscribing as demonstrated by Klebe in 1986, three dimensional (3D) bioprinting has made a substantial leap forward, particularly in the last decade. It has been widely used in fabrication of living tissues for various application areas such as tissue engineering and regenerative medicine research, transplantation and clinics, pharmaceutics and high-throughput screening, and cancer research. As bioprinting has gained interest in the medical and pharmaceutical communities, the demand for bioprinters has risen substantially. A myriad of bioprinters have been developed at research institutions worldwide and several companies have emerged to commercialize advanced bioprinter technologies. This paper prefaces the evolution of the field of bioprinting and presents the first comprehensive review of existing bioprinter technologies. Here, a comparative evaluation is performed for bioprinters; limitations with the current bioprinter technologies are discussed thoroughly and future prospects of bioprinters are provided to the reader.
AB - Since the first printing of biologics with cytoscribing as demonstrated by Klebe in 1986, three dimensional (3D) bioprinting has made a substantial leap forward, particularly in the last decade. It has been widely used in fabrication of living tissues for various application areas such as tissue engineering and regenerative medicine research, transplantation and clinics, pharmaceutics and high-throughput screening, and cancer research. As bioprinting has gained interest in the medical and pharmaceutical communities, the demand for bioprinters has risen substantially. A myriad of bioprinters have been developed at research institutions worldwide and several companies have emerged to commercialize advanced bioprinter technologies. This paper prefaces the evolution of the field of bioprinting and presents the first comprehensive review of existing bioprinter technologies. Here, a comparative evaluation is performed for bioprinters; limitations with the current bioprinter technologies are discussed thoroughly and future prospects of bioprinters are provided to the reader.
UR - http://www.scopus.com/inward/record.url?scp=85006954183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006954183&partnerID=8YFLogxK
U2 - 10.1016/j.addma.2016.10.003
DO - 10.1016/j.addma.2016.10.003
M3 - Review article
AN - SCOPUS:85006954183
SN - 2214-8604
VL - 13
SP - 179
EP - 200
JO - Additive Manufacturing
JF - Additive Manufacturing
ER -
